BARD1 Life Sciences Ltd
ASX:BD1
Fundamental Analysis
Revenue & Expenses Breakdown
BARD1 Life Sciences Ltd
Balance Sheet Decomposition
BARD1 Life Sciences Ltd
| Current Assets | 5.6m |
| Cash & Short-Term Investments | 5m |
| Receivables | 219.6k |
| Other Current Assets | 430.4k |
| Non-Current Assets | 27.9m |
| PP&E | 1.7m |
| Intangibles | 15.1m |
| Other Non-Current Assets | 11m |
Free Cash Flow Analysis
BARD1 Life Sciences Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
BARD1 Life Sciences Ltd
|
Revenue
|
511k
AUD
|
|
Cost of Revenue
|
-64.1k
AUD
|
|
Gross Profit
|
446.9k
AUD
|
|
Operating Expenses
|
-7.3m
AUD
|
|
Operating Income
|
-6.8m
AUD
|
|
Other Expenses
|
-4.3m
AUD
|
|
Net Income
|
-11.2m
AUD
|
BD1 Profitability Score
Profitability Due Diligence
BARD1 Life Sciences Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
BARD1 Life Sciences Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
BD1 Solvency Score
Solvency Due Diligence
BARD1 Life Sciences Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
BARD1 Life Sciences Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BD1 Price Targets Summary
BARD1 Life Sciences Ltd
Dividends
Current shareholder yield for
BD1 is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?